KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.

Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, Matthew I Milowsky, Michael Schenker, Begoña P Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebret, Shahrokh F Shariat, Se Hoon Park, Mads Agerbaek, Gautam Jha, Frank Stenner, Dingwei Ye, Fabio Giudici, Santanu Dutta, Margarita Askelson, Federico Nasroulah, Joshua Zhang, Lynne Brophy, Dean F Bajorin

J Clin Oncol 43(1) 15-21

PMID39393026
PMCIDPMC11687940
DOI10.1200/JCO.24.00340
发表日期2024-10-11
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:已完成可用 Figure 的视觉复核,未识别到合格 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIG 1.:森林图/亚组分析图;FIG 2.:森林图/亚组分析图。
摘要

摘要

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.CheckMate 274 is a phase III, randomized, double-blind trial of adjuvant nivolumab versus placebo for muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence after radical resection. The primary end points of disease-free survival (DFS) in intent-to-treat (ITT) and tumor PD-L1 expression ≥1% populations were met. We report results at an extended median follow-up of 36.1 months in the ITT population. In addition, we report interim overall survival (OS) data for the first time and an exploratory analysis among patients with bladder primary tumors (muscle-invasive bladder cancer [MIBC]). Consistent DFS benefit with nivolumab versus placebo was observed in both the ITT (hazard ratio [HR], 0.71 [95% CI, 0.58 to 0.86]) and PD-L1 ≥1% (HR, 0.52 [95% CI, 0.37 to 0.72]) patients. The HR for OS with nivolumab versus placebo was 0.76 (95% CI, 0.61 to 0.96) in the ITT population and 0.56 (95% CI, 0.36 to 0.86) in the PD-L1 ≥1 population. Continuous benefit in nonurothelial tract recurrence-free survival and distant metastasis-free survival was also observed in both patient populations. The exploratory analysis of patients with MIBC also showed continued efficacy benefits, irrespective of PD-L1 status. No new safety signals were reported. Overall, these results further support adjuvant nivolumab as a standard of care for high-risk MIUC after radical resection.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.(A) Disease-free survival. (B) Overall survival. (C) Nonurothelial tract recurrence-free survival. (D) Distant metastasis-free survival. (E) Second progression-free survival. Kaplan-Meier estimates of efficacy outcomes in ITT patients. Marks indicate censored observations. a Subsequent systemic therapies categorized as adjuvant (n = 6) were not considered in PFS2 derivation. DFS, disease-free survival (the time between the date of random assignment and the date of first recurrence [local urothelial tract, local nonurothelial tract [in pelvic soft tissue or involving pelvic nodes below the aortic bifurcation, or distant] or death [of any cause], whichever occurred first); DMFS, distant metastasis-free survival (the time between the date of random assignment and the date of first distant recurrence [non-local] or date of death [whatever the cause], whichever occurred first); HR, hazard ratio; ITT, intent-to-treat; NE, not estimable; NUTRFS, nonurothelial tract recurrence-free survival (the time between the date of random assignment and the date of first local nonurothelial tract or distant recurrence or death [of any cause], whichever occurred first); OS, overall survival (time between the date of random assignment and the date of death [of any cause]); PFS2, second progression-free survival (time from random assignment to disease progression after subsequent next-line systemic anticancer therapy, start of second subsequent next-line systemic anticancer therapy, or death from any cause, whichever occurred first).
非 KM Figure
FIG 2.(A) Disease-free survival. (B) Overall survival. (C) Nonurothelial tract recurrence-free survival. (D) Distant metastasis-free survival. (E) Second progression-free survival. Kaplan-Meier estimates of efficacy outcomes in patients with tumor PD-L1 expression ≥1%. Marks indicate censored observations. a Subsequent systemic therapies categorized as adjuvant (n = 2) were not considered in PFS2 derivation. DFS, disease-free survival (the time between the date of randomization and the date of first recurrence [local urothelial tract, local nonurothelial tract (in pelvic soft tissue or involving pelvic nodes below the aortic bifurcation), or distant] or death [of any cause], whichever occurred first); DMFS, distant metastasis-free survival (the time between the date of random assignment and the date of first distant recurrence [nonlocal] or date of death [whatever the cause], whichever occurred first); HR, hazard ratio; NR, not reached; NUTRFS, nonurothelial tract recurrence-free survival (the time between the date of random assignment and the date of first local nonurothelial tract or distant recurrence or death [of any cause], whichever occurred first); OS, overall survival (time between the date of random assignment and the date of death [of any cause]); PFS2, second progression-free survival (time from random assignment to disease progression after subsequent next-line systemic anticancer therapy, start of second subsequent next-line systemic anticancer therapy, or death from any cause, whichever occurred first).
非 KM Figure